Document is current
Any future updates will be listed below
-
Authors
Priest, Katherine
Le, Anh
Gebregzabheir, Amanuail
Nijmeh, Hala
Reis, Gregory B.
Mandell, Melanie
Davies, Kurtis D.
Lawrence, Carolyn
O’Donnell, Emily
Doebele, Robert C.
Bao, Liming
Aisner, Dara L.
Schenk, Erin L. https://orcid.org/0000-0001-9418-9948
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K12 CA086913)
LUNGevity Foundation (25B1267)
- License Information
-
More Information
Article History
Received: 2 August 2022
Accepted: 11 January 2023
First Online: 23 January 2023
Competing interests
: K.D.D. received sponsored travel from ArcherDX. R.C.D. has royalties or licenses through Rain Therapeutics, Foundation Medicine, Takeda, Pearl River, Scorpion Therapeutics, ThermoFisher, Genentech, Black Diamond, Voronoi, received consulting fees from Rain Therapeutics, Anchiano, Blueprint Medicines, Takeda, AstraZeneca, Genentech/Roche, Bayer, AstraZeneca, Green Peptide, received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Medscape, Princess Margaret Hospital, Targeted Oncology, OncLive, received support for attending meetings and/or travel: Genentech/Roche, Blueprint Medicines, Rain Therapeutics, has patents planned, issued or pending: Rain Therapeutics, Abbott Molecular, has a leadership or fiduciary role with Rain Therapeutics serves on the advisory board of Rain Therapeutics. D.L.A. reports consulting fees from Takeda, Sonif-Genzyme, Loxo Oncology, Bluepring Medicines, and Genentech. E.L.S. reports speaker fees from OncLive, Physicians’ Education Resource, Takeda, Roche/Genetech, IDEO Oncology, Sanofi/Regeneron, consultant fees from Actinium, Bionest Partners, ExpertConnect, FCB Health, Guidepoint Network, the KOL Connection Ltd, Prescient Advisory, served on an advisory board for Regeneron, Janssen, and G1 therapeutics. No other authors have any competing interests to disclose.
